Sickle Cell Disease, SCD Biochip
Sickle Cell Disease (SCD) Biochip: Towards a Simple and Reliable Way to Monitor Sickle Cell Disease.
- Sex at Birth: Any
- Age: Child (Birth - 17), Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: Yes
- Type: Others
- Trial Phase: NA
- Conditions Being Studied: Sickle Cell Trait
Study Purpose
Sickle-shaped' anemia was first clinically described in the US in 1910, and the mutated heritable sickle hemoglobin molecule was identified in 1949. The pathophysiology of SCD is a consequence of abnormal polymerization of sickle hemoglobin (HbS) and its effects on red cell membrane properties, shape, and density, and subsequent critical changes in inflammatory cell and endothelial cell function. Our goal is to understand the impact of CMA abnormalities in SCD, by interrogating a number of recognized interactions in a range of clinical phenotypes.
Who Can Participate
Age: 1 month and older
Locations
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: 05-14-07C
- StudyID: 05-14-07C
- ClinicalTrials.gov: NCT02824471
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422